Pulse Biosciences (PLSE) Operating Leases (2019 - 2026)

Pulse Biosciences has reported Operating Leases for 8 years, with the latest figure at $5.1 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 38.31% year-over-year to $5.1 million in Q2 2026; TTM through Jun 2026 was $5.1 million, a 38.31% decrease from a year earlier, with the FY2025 full-year figure at $6.0 million, down 20.99% from the prior year.
• Operating Leases was $5.1 million for Q2 2026 at Pulse Biosciences, down from $6.0 million in the prior quarter.
• The five-year high for Operating Leases was $10.0 million in Q4 2022, with the low at $5.1 million in Q2 2026.
• Average Operating Leases over 5 years is $8.6 million, with a median of $8.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases climbed 24.17% in 2022, then sank 38.31% in 2026.
• Over 5 years, Operating Leases stood at $10.0 million in 2022, then decreased by 8.92% to $9.1 million in 2023, then decreased by 17.51% to $7.5 million in 2024, then slipped by 20.99% to $6.0 million in 2025, then dropped by 14.66% to $5.1 million in 2026.
• The last three Operating Leases figures came in at $5.1 million (Q2 2026), $6.0 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.